

# Jeffrey D Lifson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6938211/publications.pdf>

Version: 2024-02-01

72  
papers

9,524  
citations

76326

40  
h-index

82547

72  
g-index

78  
all docs

78  
docs citations

78  
times ranked

8161  
citing authors

#	ARTICLE	IF	CITATIONS
1	Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. <i>Nature</i> , 2011, 473, 523-527.	27.8	902
2	Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. <i>Nature Medicine</i> , 2009, 15, 293-299.	30.7	621
3	Glycerol monolaurate prevents mucosal SIV transmission. <i>Nature</i> , 2009, 458, 1034-1038.	27.8	563
4	Immune clearance of highly pathogenic SIV infection. <i>Nature</i> , 2013, 502, 100-104.	27.8	548
5	B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. <i>Nature Medicine</i> , 2015, 21, 132-139.	30.7	439
6	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. <i>Nature</i> , 2013, 503, 277-280.	27.8	424
7	Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. <i>Nature</i> , 2014, 511, 601-605.	27.8	422
8	Cytomegalovirus Vectors Violate CD8 <sup>+</sup> T Cell Epitope Recognition Paradigms. <i>Science</i> , 2013, 340, 1237874.	12.6	397
9	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. <i>Science Translational Medicine</i> , 2015, 7, 319ra206.	12.4	390
10	Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. <i>Journal of Medical Primatology</i> , 2005, 34, 303-312.	0.6	311
11	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	12.6	303
12	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. <i>Nature</i> , 2016, 533, 105-109.	27.8	281
13	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. <i>Nature</i> , 2015, 519, 87-91.	27.8	265
14	Gag-Specific CD8 <sup>+</sup> T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression. <i>Journal of Immunology</i> , 2007, 178, 2746-2754.	0.8	247
15	Early antibody therapy can induce long-lasting immunity to SHIV. <i>Nature</i> , 2017, 543, 559-563.	27.8	244
16	Defining HIV and SIV Reservoirs in Lymphoid Tissues. <i>Pathogens and Immunity</i> , 2016, 1, 68.	3.1	212
17	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	7.1	170
18	ADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIVmac251 Challenge. <i>PLoS Pathogens</i> , 2012, 8, e1002890.	4.7	156

#	ARTICLE	IF	CITATIONS
19	A macaque model of HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4425-4429.	7.1	150
20	Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys. Cell, 2016, 165, 656-667.	28.9	144
21	Generation of Simian-Tropic HIV-1 by Restriction Factor Evasion. Science, 2006, 314, 95-95.	12.6	140
22	New Paradigms for HIV/AIDS Vaccine Development. Annual Review of Medicine, 2012, 63, 95-111.	12.2	139
23	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV <sub>mac251</sub> Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. Journal of Virology, 2013, 87, 1708-1719.	3.4	130
24	Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science, 2016, 353, 1045-1049.	12.6	129
25	Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nature Medicine, 2018, 24, 1430-1440.	30.7	98
26	A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. Science Translational Medicine, 2019, 11, .	12.4	80
27	AAV-Delivered Antibody Mediates Significant Protective Effects against SIV <sub>mac239</sub> Challenge in the Absence of Neutralizing Activity. PLoS Pathogens, 2015, 11, e1005090.	4.7	77
28	Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. PLoS Pathogens, 2017, 13, e1006359.	4.7	77
29	HIV-1-induced AIDS in monkeys. Science, 2014, 344, 1401-1405.	12.6	76
30	Comparative Characterization of Transfection- and Infection-Derived Simian Immunodeficiency Virus Challenge Stocks for <i>In Vivo</i> Nonhuman Primate Studies. Journal of Virology, 2013, 87, 4584-4595.	3.4	71
31	DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2975-2980.	7.1	71
32	The Frequency of $10^7$ high Memory CD4 <sup>+</sup> T Cells Correlates With Susceptibility to Rectal Simian Immunodeficiency Virus Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 325-331.	2.1	60
33	Impact of early cART in the gut during acute HIV infection. JCI Insight, 2016, 1, .	5.0	56
34	The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4 <sup>+</sup> T Cell Recovery: A Randomized Crossover Trial. PLoS ONE, 2014, 9, e116306.	2.5	56
35	Reduced Inflammation and Lymphoid Tissue Immunopathology in Rhesus Macaques Receiving Anti-Tumor Necrosis Factor Treatment During Primary Simian Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2013, 207, 880-892.	4.0	54
36	Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIV <sub>mac251</sub> at Challenge Exposure. Journal of Virology, 2013, 87, 3538-3548.	3.4	52

#	ARTICLE	IF	CITATIONS
37	Tracking the Luminal Exposure and Lymphatic Drainage Pathways of Intravaginal and Intrarectal Inocula Used in Nonhuman Primate Models of HIV Transmission. <i>PLoS ONE</i> , 2014, 9, e92830.	2.5	50
38	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836.	12.4	50
39	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. <i>Cell Host and Microbe</i> , 2014, 16, 412-418.	11.0	47
40	Molecularly Tagged Simian Immunodeficiency Virus SIVmac239 Synthetic Swarm for Tracking Independent Infection Events. <i>Journal of Virology</i> , 2014, 88, 8077-8090.	3.4	46
41	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	45
42	Longitudinal in Vivo Positron Emission Tomography Imaging of Infected and Activated Brain Macrophages in a Macaque Model of Human Immunodeficiency Virus Encephalitis Correlates with Central and Peripheral Markers of Encephalitis and Areas of Synaptic Degeneration. <i>American Journal of Pathology</i> , 2008, 172, 1603-1616.	3.8	44
43	Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. <i>Molecular Therapy</i> , 2019, 27, 650-660.	8.2	42
44	Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 546-554.	3.8	40
45	Control of Heterologous Simian Immunodeficiency Virus SIV <sub>smE660</sub> Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	39
46	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIV <sub>smE660</sub> challenge. <i>PLoS Pathogens</i> , 2018, 14, e1007395.	4.7	37
47	AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	35
48	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. <i>Journal of Immunology</i> , 2014, 193, 6172-6183.	0.8	34
49	Cytomegaloviral determinants of CD8 <sup>+</sup> T cell programming and RhCMV/SIV vaccine efficacy. <i>Science Immunology</i> , 2021, 6, .	11.9	34
50	Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy. <i>Science</i> , 2021, 372, .	12.6	32
51	Blocking $\alpha_4\beta_7$ integrin binding to SIV does not improve virologic control. <i>Science</i> , 2019, 365, 1033-1036.	12.6	31
52	Defining early SIV replication and dissemination dynamics following vaginal transmission. <i>Science Advances</i> , 2019, 5, eaav7116.	10.3	30
53	Evaluation of an antibody to $\alpha_4\beta_7$ in the control of SIVmac239- <i>nef-stop</i> infection. <i>Science</i> , 2019, 365, 1025-1029.	12.6	29
54	Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV. <i>Frontiers in Immunology</i> , 2020, 11, 449.	4.8	29

#	ARTICLE	IF	CITATIONS
55	A single gp120 residue can affect HIV-1 tropism in macaques. PLoS Pathogens, 2017, 13, e1006572.	4.7	28
56	<i>In Vivo</i> Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses. Journal of Virology, 2019, 94, .	3.4	24
57	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure. Journal of Virology, 2021, 95, .	3.4	21
58	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	4.7	20
59	Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. Journal of Virology, 2016, 90, 8435-8453.	3.4	19
60	Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy. PLoS Pathogens, 2021, 17, e1009278.	4.7	18
61	Restricted Replication of Xenotropic Murine Leukemia Virus-Related Virus in Pigtailed Macaques. Journal of Virology, 2012, 86, 3152-3166.	3.4	16
62	Myeloid cell tropism enables MHC-E $\alpha$ -restricted CD8 <sup>+</sup> T cell priming and vaccine efficacy by the RhCMV/SIV vaccine. Science Immunology, 2022, 7, .	11.9	16
63	Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy. Journal of Virology, 2009, 83, 1501-1510.	3.4	14
64	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10504-10509.	7.1	14
65	Genetically barcoded SIV reveals the emergence of escape mutations in multiple viral lineages during immune escape. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 494-502.	7.1	9
66	Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions. Journal of Virology, 2018, 92, .	3.4	8
67	Generation and characterization of a SIVmac239 clone corrected at four suboptimal nucleotides. Retrovirology, 2015, 12, 49.	2.0	6
68	Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies. Molecular Therapy - Methods and Clinical Development, 2020, 16, 225-237.	4.1	5
69	Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques. PLoS ONE, 2020, 15, e0228163.	2.5	4
70	Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques. Frontiers in Immunology, 2021, 12, 657424.	4.8	2
71	Recombinant Herpesvirus Vectors: Durable Immune Responses and Durable Protection against Simian Immunodeficiency Virus SIVmac239 Acquisition. Journal of Virology, 2021, 95, e0033021.	3.4	2
72	Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. Journal of Clinical Investigation, 2021, 131, .	8.2	1